Patent SG-11201909749P-A (SG)
Title: Oncolytic virotherapy and immunotherapy
Inventor: SUZUKI MASATAKA
IPC: C07K19/00
Filed: 2018-04-20
Abstract: AdVST1CAR AdVST Or c.Ad if t .CAR AdVST CAdtrio +1 7 1..CAR AdVS1- *.* (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 25 October 2018 (25.10.2018) WIPO I PCT 11111IIIIIII101111111111111111111111101011101111111111111111111111111111111101111001111 (10) International Publication Number WO 2018/195427 A3 (51) International Patent Classification: A 61K 35/768 (2015.01) C07K 14/705 (2006.01) C07K 16/28 (2006.01) C07K 19/00 (2006.01) C07K 16/32 (2006.01) Cl2N 5/0783 (2010.01) A61K 38/20 (2006.01) A61P 35/00 (2006.01) C07K 14/725 (2006.01) (21) International Application Number: PCT/US2018/028577 (22) International Filing Date: 20 April 2018 (20.04.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/488,181 21 April 2017 (21.04.2017) US (71) Applicant: BAYLOR COLLEGE OF MEDICINE [US/US]; One Baylor Plaza, Houston, TX 77030 (US). (72) Inventors: SUZUKI, Masataka; 7575 Kirby Drive, #2215, Houston, TX 77030 (US). ROSEWELL SHAW, Amanda; 12304 Winebrook Drive, Pearland, TX (US). PORTER, Caroline, Elaine; 7009 Almeda Road, #820, Houston, TX 77054 (US). WATANABE, Norihiro; 7550 Kirby Drive, #1542, Houston, TX 77030 (US). BRENNER, Malcolm, K.; 4802 Willow, Bellaire, TX 77401 (US). (74) Agent: SISTRUNK, Melissa, L. et al.; Norton Rose Ful- bright US LLP, 1301 McKinney, Suite 5100, Houston, TX 77010-3095 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, 1E, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). (54) Title: ONCOLYTIC VIROTHERAPY AND IMMUNOTHERAPY 10 20 30 Days post-injection of CM Figure 24D (57) : The present disclosure concerns combination therapy for cancer that utilizes (i) an oncolytic vims; (ii) a vims comprising nucleic acid encoding an immunomodulatory factor; and (iii) at least one cell comprising a chimeric antigen receptor (CAR) specific for a cancer cell antigen. In particular embodiments, the virus comprises nucleic acid encoding an immunomodulatmy factor comprises nucleic acid encoding IL-12 and/or antagonist anti-PD-Ll antibody. [Continued on next page] 100 BO 40 03 20 WO 2018/195427 A3 I IIIII I 01111101110101111111101111101011101MMIEHHHIMEMM01111 Published: with international search report (Art. 21(3)) before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h)) with sequence listing part of description (Rule 5.2(a)) (88) Date of publication of the international search report: 28 February 2019 (28.02.2019)